Revolution Medicines (RVMD) Operating Leases (2020 - 2026)

Revolution Medicines has reported Operating Leases for 7 years, with the latest figure at $137.7 million in Q2 2026.

• On a quarterly basis, Operating Leases rose 15.07% year-over-year to $137.7 million in Q2 2026; TTM through Jun 2026 was $137.7 million, a 15.07% increase from a year earlier, with the FY2025 full-year figure at $142.2 million, up 15.66% from the prior year.
• Operating Leases was $137.7 million for Q2 2026 at Revolution Medicines, down from $140.0 million in the prior quarter.
• The five-year high for Operating Leases was $142.2 million in Q4 2025, with the low at $57.1 million in Q3 2023.
• Average Operating Leases over 5 years is $91.7 million, with a median of $79.5 million recorded in 2024.
• The largest YoY upside for Operating Leases was 116.88% in 2022 against a maximum downside of 4.94% in 2022.
• Over 5 years, Operating Leases stood at $57.4 million in 2022, then soared by 40.3% to $80.6 million in 2023, then soared by 52.62% to $123.0 million in 2024, then increased by 15.66% to $142.2 million in 2025, then fell by 3.16% to $137.7 million in 2026.
• The last three Operating Leases figures came in at $137.7 million (Q2 2026), $140.0 million (Q1 2026), and $142.2 million (Q4 2025), per Business Quant data.